Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2

Interventions

Cyclophosphamide 192Methotrexate 106Cytarabine 86fludarabine phosphate 80Busulfan 71Tacrolimus 70Peripheral Blood Stem Cell Transplantation 69Mycophenolic Acid 69Whole-Body Irradiation 68Vincristine 67fludarabine 61Filgrastim 61Etoposide 59Dexamethasone 54Melphalan 52Radiotherapy 47Rituximab 46Cyclosporine 46Doxorubicin 38Antilymphocyte Serum 37Thiotepa 35Granulocyte Colony-Stimulating Factor 35Prednisone 34Mercaptopurine 34blinatumomab 33pegaspargase 27Methylprednisolone 27Daunorubicin 26Clofarabine 26Asparaginase 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Precursor Cell Lymphoblastic Leukemia-Lymphoma × palmitoyl-L-asparaginase × Clear all
NCT00873093 2017-01-27

Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

National Cancer Institute (NCI)

Phase 2 Completed
148 enrolled 19 charts
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00262925 2015-05-05

Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 2 Terminated
12 enrolled 6 charts
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡